



The influence of chemotherapy on adenosine-producing B cells in patients with head and neck squamous cell carcinoma

SUPPLEMENTARY MATERIALS



Supplementary Figure 1: (A and B) Frequencies of CD4⁺ T cells and CD19⁺ B cells were determined by flow cytometry before and after a platinum or MTX-based therapy, respectively. (C) The percentage of IgM-expressing B cells increased after CRT. (D) Adenosine-producing B cells showed no alteration in frequency after MTX-based treatment, gated on CD19⁺ B cells. (E and F) CD19⁺IgA⁺ cells were not affected by systemic antineoplastic treatment. (G) CD39 expression on B cells, and therefore ATP hydrolysis, was impaired by paclitaxel dose-dependently.



Supplementary Figure 2: Representative example of human B cells (precultured with IL-4, CD40L and hemagglutinin) from one healthy donor incubated with no cytostatic, 1 μg/mL and 3 μg/mL paclitaxel showing dose-dependent impairment of B cell proliferation measured by flow cytometry through dilution of CFSE.